Optimizing antibody leads in early drug discovery with key developability insights

Supported by:

30 July 2025

9:00am

Shares

0

Share via

• Facebook
• Like
• Twitter
• Pinterest
• LinkedIn
• Digg
• Del
• Tumblr
• VKontakte
• Print
• Email
• Reddit
• Buffer
• Love This
• Weibo
• Pocket
• Xing
• Odnoklassniki
• WhatsApp
• Meneame
• Blogger
• Amazon
• Yahoo Mail
• Gmail
• AOL
• Newsvine
• HackerNews
• Evernote
• MySpace
• Mail.ru
• Viadeo
• Line
• Flipboard
• Comments
• Yummly
• SMS
• Viber
• Telegram
• Subscribe
• Skype
• Facebook Messenger
• Kakao
• LiveJournal
• Yammer
• Edgar
• Fintel
• Mix
• Instapaper
• Copy Link

Biologics discovery often prioritises potency and binding, but many leads fail in development due to unresolved issues like poor stability, aggregation, or low PK. Early-stage developability assessment helps flag these risks before molecules advance into CMC development.

This webinar will explore practical strategies for evaluating critical developability attributes early, using high-throughput approaches that require <1 mg antibody per assay. Introducing a strategy that integrates in silico modelling with high-throughput in vitro assays to support early lead optimization – without demanding large sample volumes or long turnaround times.

Attendees will learn how to incorporate early developability assessment into discovery-stage programs using high-throughput methods that require minimal material and offer rapid turnaround, helping to mitigate costly downstream risks.

To support this, WuXi Biologics will present its Micro Developability platform: a high-throughput analytical suite that combines in silico and in vitro tools to assess key developability risks using less than 1 mg of antibody per assay – delivering expert interpretation and actionable insights to guide lead optimization.

The webinar will offer clear guidance on how to evaluate early-stage biologics leads using both in silico analysis and high-throughput wet-lab assays.

Key learning points: 

• Learn how to assess key developability risks early, including PK, stability, and manufacturability, using less than 1 mg of material per assay
• Explore high-throughput, sensitive assays such as AC-SINS, DNA/Insulin ELISA, FcRn affinity, and serum stability to support early-stage antibody optimization
• Discover how in silico modeling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
• Understand how micro-developability strategies are tailored for complex or novel formats, including Fc-lacking biologics
• Ask Dr Lei Guo your questions and benefit from her hands-on experience in developability optimization and advanced analytics

Dr Lei Guo will also provide an overview of the comprehensive protein analytics platform, including mass spectrometry, purity and impurity analysis, binding assays, and biophysical characterization. She will share how these tools can be integrated into a tailored Micro Developability package to support specific drug discovery needs.

Register now to secure your place >>>

SPEAKER

Lei Guo, Ph.D. – Director of CRO Services

Dr. Lei Guo leads the Protein Analytical Chemistry group in WuXi Biologics CRO Services Department. Her team specializes in comprehensive analytical testing of monoclonal antibodies, bispecific antibodies, ADCs, and fusion proteins in drug discovery and optimization stages, employing Mass Spectrometry and physicochemical and biophysical analyses. With over 14 years of experience in bioanalysis, Dr. Guo has held diverse roles at Pfizer, Sanofi, and MSD, contributing to target discovery, drug development, and CMC-stage analysis.  

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 30 July 10:00 AM BST. 

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.

CASE STUDIES

• Identification of CDR hotspots, post-translational modification risks, and aggregation scores using in silico tools
• Evaluation of self-association tendencies using AC-SINS and HIC
• Assessment of non-specific binding via BVP/DNA/Insulin ELISA, clearance through FcRn affinity, and half-life using serum stability assays
• Stress testing under low pH, thermal (40°C), and freeze/thaw conditions
• Troubleshooting charged variants with CIEF-MS
• Optimization of antibody candidates to improve expression, reduce degradation and aggregation, enhance thermal stability, and extend half-life